• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cost-effectiveness of vaccinating pregnant women against pandemic influenza in Colombia

tetano

Editor, Senior Moderator
Rev Panam Salud Publica. 2012 Jun;31(6):447-53.
[Cost-effectiveness of vaccinating pregnant women against pandemic influenza in Colombia].
[Article in Spanish]
Chocont?-Piraquive LA, Alvis Guzm?n N, De la Hoz Restrepo F.
Source

Grupo de Epidemiolog?a y Evaluaci?n en Salud P?blica, Facultad de Medicina, Universidad Nacional de Colombia, Bogot?, D.C., Colombia.
Abstract
OBJECTIVE:

Estimating the cost-effectiveness ratio of vaccinating pregnant women against the 2009 pandemic influenza A (H1N1) in Colombia during the second wave of the pandemic.
METHODS:

A decision tree was constructed, which simulated the health results (deaths and years of potential life lost [YPLL]) in two cohorts of pregnant women; one vaccinated, the other unvaccinated. The model's parameters were drawn from scientific literature and costs were estimated on the basis of a previous study. Incremental cost-effectiveness ratios (ICER) were calculated.
RESULTS:

Vaccinating pregnant women against pandemic flu would have prevented between 4 664 and 15 741 outpatient visits and between 119 and 401 hospitalizations. Between US$ 249 530 and US$ 842 163 in costs of care would have been avoided. For the base scenario, vaccinating pregnant women would be cost-effective (ICER/YPLL avoided US$ 7 657). This ICER was responsive to the disease's fatality rate; vaccina tion would not be cost-effective in Colombia in scenarios with a lower fatality rate.
CONCLUSIONS:

Vaccinating pregnant women against pandemic influenza is cost-effective in a scenario with a high mortality rate. The existing evidence that pregnant women are at increased risk of complications and that the vaccine is safe would justify its use in pregnant women.

PMID:
22858810
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/22858810
 
Back
Top Bottom